Proposed daratumumab biosimilar by Biocad; a fully human IgG1κ monoclonal antibody targeting CD38 that induces CDC, ADCC, ADCP, apoptosis, and modulates CD38 NADase activity.
BCD-264 is a daratumumab biosimilar, a fully human IgG1κ monoclonal antibody targeting CD38. It depletes CD38-expressing cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), can induce apoptosis upon cross-linking, and modulates/inhibits CD38 NADase enzymatic activity.
Anti-CD38 IgG1 binds CD38 on target cells and eliminates them via complement-dependent cytotoxicity, Fc-mediated ADCC by NK/effector cells, antibody-dependent phagocytosis, and apoptosis upon cross-linking.
Daratumumab; a fully human IgG1κ monoclonal antibody against CD38 that mediates CDC, ADCC, ADCP, induces apoptosis, and modulates CD38 NADase activity.
Daratumumab is a fully human IgG1κ monoclonal antibody targeting CD38 on plasma cells; it depletes CD38+ cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), can induce apoptosis upon crosslinking, and modulates CD38 ectoenzyme (NADase) activity, disrupting CD38/NAD+ signaling.
Daratumumab binds CD38 on target cells and triggers complement-dependent lysis (CDC), FcγR-mediated ADCC and ADCP by immune effector cells, and can induce apoptosis upon crosslinking.
Oncolytic viral immunotherapy (PVSRIPO), a live-attenuated poliovirus type 1 Sabin/rhinovirus chimera that targets CD155/Necl-5 on tumor and antigen-presenting cells, replicates to cause oncolysis and antigen release, and induces type I IFN and dendritic-cell activation to drive tumor-specific T-cell responses.
Live-attenuated poliovirus type 1 Sabin/human rhinovirus HRV2 IRES chimera that targets CD155 (Necl-5) on tumor and antigen-presenting cells; selectively replicates in CD155+ nonneuronal tumor cells causing oncolysis and antigen release, which triggers type I interferon signaling and dendritic-cell activation to drive tumor-specific T-cell responses and systemic antitumor immunity.
The oncolytic poliovirus binds CD155 to enter CD155+ tumor cells, selectively replicates inside them, and causes lytic cell death (oncolysis); immune activation occurs secondarily.
Engineered protein cytotoxin that binds integrin αvβ3 and induces apoptosis in αvβ3-expressing cells to remodel the tumor microenvironment.
Engineered protein cytotoxin that binds integrin αvβ3 and induces caspase-mediated apoptosis in αvβ3-expressing stromal, endothelial, and tumor cells, depleting these populations and remodeling the tumor microenvironment.
Binds integrin αvβ3 on target cells and triggers caspase-mediated apoptosis, directly killing αvβ3-expressing cells.
Engineered protein cytotoxin that binds integrin αvβ3 and induces apoptosis in αvβ3-expressing cells to remodel the tumor microenvironment.
Engineered protein cytotoxin that binds integrin αvβ3 and induces caspase-mediated apoptosis in αvβ3-expressing stromal, endothelial, and tumor cells, depleting these populations and remodeling the tumor microenvironment.
ProAgio binds integrin αvβ3 on target cells and directly triggers caspase-dependent apoptosis, killing αvβ3-expressing stromal, endothelial, and tumor cells.